Jefferies Financial Group Inc. Acquires New Stake in Delcath Systems, Inc. (NASDAQ:DCTH)

Jefferies Financial Group Inc. purchased a new position in Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 20,806 shares of the company's stock, valued at approximately $251,000. Jefferies Financial Group Inc. owned approximately 0.07% of Delcath Systems as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Quarry LP purchased a new stake in shares of Delcath Systems in the fourth quarter worth about $34,000. Quantbot Technologies LP bought a new stake in Delcath Systems in the 4th quarter worth approximately $66,000. Barclays PLC purchased a new stake in shares of Delcath Systems during the 3rd quarter worth approximately $104,000. Graham Capital Management L.P. bought a new position in shares of Delcath Systems during the 4th quarter valued at approximately $123,000. Finally, Private Advisor Group LLC bought a new position in shares of Delcath Systems during the 4th quarter valued at approximately $153,000. Institutional investors own 61.12% of the company's stock.

Delcath Systems Stock Performance

DCTH stock traded down $0.13 during midday trading on Tuesday, reaching $17.97. 404,994 shares of the company traded hands, compared to its average volume of 367,329. The firm has a market capitalization of $625.82 million, a price-to-earnings ratio of -13.31 and a beta of 0.72. Delcath Systems, Inc. has a 52-week low of $6.33 and a 52-week high of $18.21. The business has a 50 day moving average of $12.85 and a 200-day moving average of $12.86.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.03 earnings per share for the quarter, missing analysts' consensus estimates of $0.10 by ($0.07). The firm had revenue of $19.80 million for the quarter, compared to the consensus estimate of $16.83 million. Delcath Systems had a negative net margin of 150.70% and a negative return on equity of 338.16%. Research analysts anticipate that Delcath Systems, Inc. will post -0.79 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright boosted their price target on shares of Delcath Systems from $22.00 to $24.00 and gave the stock a "buy" rating in a research report on Friday, March 7th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $22.75.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.